Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Immunologic diseases, anti-inflammatory drugs, and Parkinson disease: a case-control study.

Literature DB >> 16894114

Immunologic diseases, anti-inflammatory drugs, and Parkinson disease: a case-control study.

J H Bower¹, D M Maraganore, B J Peterson, J E Ahlskog, W A Rocca.

Abstract

The authors studied the association of markers of inflammation with the later development of Parkinson disease (PD) using a case-control design (196 cases and 196 matched controls). The frequency of diseases of immediate-type hypersensitivity was significantly higher in cases than controls. In addition, cases used anti-inflammatory agents less frequently than controls (nonsignificant trend). The results may support the hypothesis that there is an inflammatory component in the pathogenesis of PD.

Entities: Disease

Mesh：

Substances：
Anti-Inflammatory Agents

Year: 2006 PMID： 16894114 DOI： 10.1212/01.wnl.0000227906.99570.cc

Source DB: PubMed Journal: Neurology ISSN： 0028-3878 Impact factor: 9.910

Keyword Cloud
Cited

39 in total

1. Risk factors for Parkinson's disease may differ in men and women: an exploratory study.

Authors: Rodolfo Savica; Brandon R Grossardt; James H Bower; J Eric Ahlskog; Walter A Rocca
Journal: Horm Behav Date: 2012-06-08 Impact factor: 3.587

2. Non-genetic factors associated with the risk of Parkinson's disease in Iranian patients.

Authors: N Hosseini Tabatabaei; B Babakhani; A Hosseini Tabatabaei; Z Vahabi; A Soltanzadeh
Journal: Funct Neurol Date: 2013 Apr-May

Review 3. Pathogenesis-targeted, disease-modifying therapies in Parkinson disease.

Authors: Amaal AlDakheel; Lorraine V Kalia; Anthony E Lang
Journal: Neurotherapeutics Date: 2014-01 Impact factor: 7.620

4. Cutting edge: IL-13Rα1 expression in dopaminergic neurons contributes to their oxidative stress-mediated loss following chronic peripheral treatment with lipopolysaccharide.

Authors: Brad E Morrison; Maria Cecilia Garibaldi Marcondes; Daniel K Nomura; Manuel Sanchez-Alavez; Alejandro Sanchez-Gonzalez; Indrek Saar; Kwang-Soo Kim; Tamas Bartfai; Pamela Maher; Shuei Sugama; Bruno Conti
Journal: J Immunol Date: 2012-11-19 Impact factor: 5.422

Immunologic diseases, anti-inflammatory drugs, and Parkinson disease: a case-control study.

1. Risk factors for Parkinson's disease may differ in men and women: an exploratory study.

2. Non-genetic factors associated with the risk of Parkinson's disease in Iranian patients.

Review 3. Pathogenesis-targeted, disease-modifying therapies in Parkinson disease.

4. Cutting edge: IL-13Rα1 expression in dopaminergic neurons contributes to their oxidative stress-mediated loss following chronic peripheral treatment with lipopolysaccharide.

Review 5. Microglial phenotypes in Parkinson's disease and animal models of the disease.

6. Use of ibuprofen and risk of Parkinson disease.

Review 7. Parkinson's disease and enhanced inflammatory response.

8. Cyclooxygenase and neuroinflammation in Parkinson's disease neurodegeneration.

Review 9. Glycoprotein NMB: an Emerging Role in Neurodegenerative Disease.

Review 10. The role of anti-inflammatory agents in Parkinson's disease.